<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131963</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00014267</org_study_id>
    <secondary_id>DUMC-4522-04-1-R1</secondary_id>
    <secondary_id>CDR0000438673</secondary_id>
    <nct_id>NCT00131963</nct_id>
  </id_info>
  <brief_title>A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel</brief_title>
  <official_title>A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells. Giving chemotherapy after surgery may kill any tumor cells that remain&#xD;
      after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well doxorubicin, cyclophosphamide, and/or&#xD;
      paclitaxel work in treating women with nonmetastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the pharmacogenomics of adjuvant chemotherapy comprising doxorubicin and&#xD;
           cyclophosphamide and/or paclitaxel in women with nonmetastatic invasive breast cancer.&#xD;
&#xD;
        -  Determine treatment-induced myelosuppression (e.g., neutropenia) in patients treated&#xD;
           with adjuvant doxorubicin and cyclophosphamide who have polymorphisms in drug activation&#xD;
           and metabolism genes.&#xD;
&#xD;
        -  Correlate the incidence of peripheral neuropathy with pharmacogenomic analysis in&#xD;
           patients treated with paclitaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine response (i.e., relapse in the adjuvant setting) during a 10-year follow-up&#xD;
           period in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive treatment on The Cancer and Leukemia&#xD;
      Group B study(CALGB) CALGB-40101 OR are assigned to receive 1 of 2 treatment regimens on this&#xD;
      study.&#xD;
&#xD;
        -  Regimen 1: Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over&#xD;
           30 minutes on day 1. Treatment repeats every 21 days for 4 courses.&#xD;
&#xD;
        -  Regimen 2: Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients&#xD;
           then receive paclitaxel IV over 1 hour once weekly for 12 weeks.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 3, 6, and 12 months and then&#xD;
      annually for up to 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 500 patients (300 treated with doxorubicin and cyclophosphamide&#xD;
      and 200 treated with paclitaxel) will be accrued for this study within 3-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-induced myelosuppression (e.g., neutropenia)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of peripheral neuropathy</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response (relapse in adjuvant setting) for 10 years after completion of study treatment</measure>
    <time_frame>Ten years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">94</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <description>Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <description>Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>taxol</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA will be extracted from blood samples taken at the first cycle of Doxorubicin and/or&#xD;
      Paclitaxel to analyze certain genes that may predict the severity of side-effects that may be&#xD;
      experienced with chemotherapy.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from the breast cancer oncology clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility Criteria&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
          -  node negative stage &gt; T1c or T1b with poor prognostic features (high grade, Her2/neu&#xD;
             FISH positive, ER negative) or stage 2 (T2, N0) or&#xD;
&#xD;
          -  enrolled on CALGB 40101, CALGB 49909, or the National Cancer Institute of Canada study&#xD;
             MA-21 or&#xD;
&#xD;
          -  any node positive patient or locally advanced undergoing neoadjuvant chemotherapy with&#xD;
             either AC or paclitaxel&#xD;
&#xD;
          -  Age greater than or equal to 18 years.&#xD;
&#xD;
          -  &gt;/=2 weeks from major surgery (wide excision / lumpectomy / mastectomy)&#xD;
&#xD;
          -  No evidence of systemic metastasis&#xD;
&#xD;
          -  Undergoing adjuvant treatment with standard dose AC or AC followed by weekly&#xD;
             Paclitaxel at 80mg/m2&#xD;
&#xD;
          -  Adequate bone marrow, hepatic and renal functions (absolute neutrophil count &gt;1,500/&#xD;
             μl, platelet count &gt; 100,000/ μl, serum creatinine &lt;2.0 mg/dl, total Bilirubin &lt;2.0 x&#xD;
             the upper limit of normal (ULN)&#xD;
&#xD;
          -  Ability to answer and understand study surveillance questionnaires&#xD;
&#xD;
          -  No concurrent drug therapy (within 2 weeks) with agents that are known inducers or&#xD;
             inhibitors of Cytochrome P450 (CYP450).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Other anticancer cytotoxic or endocrine therapy, immunotherapy, or biologic response&#xD;
             modifiers,Study Drugs or other concomitant medications known to cause myelosuppression&#xD;
             especially neutropenia and neuropathy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status(ECOG) functional status &gt; 2.&#xD;
&#xD;
          -  Serious co-morbidities including poorly controlled diabetes mellitus, ischaemic heart&#xD;
             disease,uncontrolled hypertension or active infection.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of growth factor during cycle 1 of chemotherapy (AC) under pharmacokinetic&#xD;
             evaluation&#xD;
&#xD;
          -  Grade &gt;/=2 peripheral neuropathy symptoms based on National Cancer Institute- Common&#xD;
             Terminology Criteria for Adverse Events (NCI-CTCAE) Scale. Exception: a chronic&#xD;
             neurologic disorder will be reviewed on a case by case basis by the study PI.&#xD;
&#xD;
          -  Prior treatment with weekly paclitaxelDISEASE CHARACTERISTICS:&#xD;
&#xD;
               -  Histologically confirmed invasive breast cancer, meeting 1 of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Node negative disease AND meets 1 of the following stage criteria:&#xD;
&#xD;
                         -  Primary tumor &gt; T1c&#xD;
&#xD;
                         -  Primary tumor &gt; T1b AND poor prognostic features, defined as the&#xD;
                            following:&#xD;
&#xD;
                              -  High-grade disease&#xD;
&#xD;
                              -  Human Epidermal Growth Factor Receptor 2 (HER2)/neu-positive&#xD;
                                 disease by fluorescence in situ hybridization&#xD;
&#xD;
                              -  Estrogen receptor-negative disease&#xD;
&#xD;
                         -  Stage II disease (T2, N0)&#xD;
&#xD;
                    -  Node positive nonmetastatic disease&#xD;
&#xD;
                    -  Locally advanced disease AND receiving neoadjuvant chemotherapy comprising&#xD;
                       doxorubicin and cyclophosphamide OR paclitaxel&#xD;
&#xD;
                    -  Enrolled in clinical trial CALGB-40101&#xD;
&#xD;
               -  No evidence of systemic metastasis&#xD;
&#xD;
               -  Hormone receptor status:&#xD;
&#xD;
                    -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul K. Marcom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2005</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage One A (IA) breast cancer</keyword>
  <keyword>stage Two (II) breast cancer</keyword>
  <keyword>stage Three A (IIIA) breast cancer</keyword>
  <keyword>stage Three B(IIIB) breast cancer</keyword>
  <keyword>stage Three C(IIIC) breast cancer</keyword>
  <keyword>stage One B (IB) breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

